8.25
1.32%
-0.11
After Hours:
8.25
Vir Biotechnology Inc stock is currently priced at $8.25, with a 24-hour trading volume of 751.03K.
It has seen a -1.32% decreased in the last 24 hours and a -23.33% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $8.42 pivot point. If it approaches the $8.20 support level, significant changes may occur.
Vir Biotechnology Inc Stock (VIR) Financials Data
Vir Biotechnology Inc (VIR) Revenue 2024
VIR reported a revenue (TTM) of $39.49 million for the quarter ending December 31, 2023, a -97.50% decline year-over-year.
Vir Biotechnology Inc (VIR) Net Income 2024
VIR net income (TTM) was -$615.06 million for the quarter ending December 31, 2023, a -219.24% decrease year-over-year.
Vir Biotechnology Inc (VIR) Cash Flow 2024
VIR recorded a free cash flow (TTM) of -$800.36 million for the quarter ending December 31, 2023, a -150.17% decrease year-over-year.
Vir Biotechnology Inc (VIR) Earnings per Share 2024
VIR earnings per share (TTM) was -$4.59 for the quarter ending December 31, 2023, a -220.47% decline year-over-year.
Vir Biotechnology Inc Stock (VIR) Latest News
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Benzinga
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
Benzinga
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
Zacks Investment Research
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Zacks Investment Research
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Cap:
|
Volume (24h):